Page last updated: 2024-11-12

avrainvillamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

avrainvillamide: from Aspergillus sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11719255
CHEMBL ID2042025
CHEBI ID131140
MeSH IDM0459040

Synonyms (7)

Synonym
CHEBI:131140
avrainvillamide
CHEMBL2042025
BRD-K10466330-001-01-5
(1s,17s,19s)-9,9,16,16-tetramethyl-14-oxido-8-oxa-23,25-diaza-14-azoniaheptacyclo[17.5.2.01,17.03,15.04,13.07,12.019,23]hexacosa-2,4(13),5,7(12),10,14-hexaene-24,26-dione
Q27224929
lsm-42688

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Avrainvillamide treatment is also shown to inhibit nuclear export of Crm1 cargo proteins, including AML-associated NPM1 mutants."( Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.
Andresen, V; Chan, KP; Gjertsen, BT; Hanley, ML; Mukherjee, H; Myers, AG, 2015
)
1.41
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-benzopyran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID667082Cytotoxicity against human MIAPaCa2 after 24 hrs by MTT assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans.
AID667072Antifungal activity against Candida albicans DAY185 assessed as lowest compound concentration causing =>80% reduction in cell viability after 48 hrs by XTT assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans.
AID667073Antifungal activity against Candida albicans DAY185 assessed as inhibition of biofilm formation after 48 hrs by XTT assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (64.29)29.6817
2010's5 (35.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.93 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]